Skip to main content
Erschienen in: Clinical Sarcoma Research 1/2015

Open Access 01.12.2015 | Research

Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases

verfasst von: Salvatore Romeo, Sabrina Rossi, Marthelena Acosta Marín, Fabio Canal, Marta Sbaraglia, Licia Laurino, Guido Mazzoleni, Maria Cristina Montesco, Laura Valori, Marta Campo Dell’Orto, Andrea Gianatti, Alexander Joseph Lazar, Angelo Paolo Dei Tos

Erschienen in: Clinical Sarcoma Research | Ausgabe 1/2015

Abstract

Background

Recently a few cases of synovial sarcoma (SS) of the abdominal viscera have been reported, raising awareness about the potential for confusion between this entity and KIT-negative gastrointestinal stromal tumors (GIST). We report the clinicopathological, immunophenotypical and molecular features of fifteen more SS occurring in the stomach (8 cases), epigastric region (one case), small intestine (one case), large intestine (three cases), involving both the terminal ileum and the caecum (one case) and liver (one case).

Methods

Immunostains for SMA, DESMIN, CD34, CD117, S100, EMA, CK AE1/3, TLE1, CD56, CD99, BCL2, DOG1 were performed. Rearrangement of SS18 gene region was screened in all cases: by conventional karyotype in one case, the remaining cases were screened either by interphase FISH or Q-PCR or both.

Results

Ten patients were male and five female, with an age range of 17–61 years (median 44). Tumor size ranged from 2 to 15 cm (median 8). Mitoses per 10 HPF ranged from 4 to 27 (median 9.5). Eleven tumors were monophasic fibrous SS, one biphasic SS and three poorly differentiated SS. SMA, Desmin, CD34, CD117 and S100 were negative in all cases, whereas EMA and/or CK AE1/AE3 were positive in all cases. TLE1, BCL2 and CD56 were positive in all tested cases. DOG1 was positive in one case. SS18 gene region rearrangement was demonstrated in all cases. A fusion transcript was amplified in eight cases: either SS18-SSX2 or SS18-SSX1 respectively in four cases each.

Conclusions

SS is increasingly recognized at visceral sites. Molecular analyses play a key role when dealing with usual histotypes in unusual sites. Correct diagnosis is crucial for appropriate therapy.
Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SR: experimental design, drafting of the manuscript; SR, FC, MAM, MS, LL, LV, MCDO: commenting on the final manuscript; GM, MCM, AG: collecting new cases; AL, APDT: collecting new cases, drafting and editing of the manuscript. All authors have read and given final approval of the version to be published.

Introduction

Synovial sarcoma (SS) is a mesenchymal malignant tumour that accounts for approximately 10% of all soft tissue sarcomas [1]. It usually occurs in the lower limbs of children and young adults, with the knee region being the most frequently affected area [1]. Three main histological variants of SS have been recognized: the monophasic, biphasic and poorly differentiated subtypes [1]. Both the monophasic and biphasic variants feature a spindle cell population set in a variable collagenous background with a hemangiopericytoma (HPC)-like vascular pattern [1]. An epithelial component is present in the biphasic variant, with solid nests and glandular or tubular structures [1]. The existence of a predominantly monophasic epithelial pattern has been reported, too [2]. In approximately 20% of cases, SS exhibits undifferentiated, high-grade morphology and is usually indicated as “poorly differentiated” SS (PDSS) [3]. Three main groups of PDSS can be identified: one exhibiting round cell morphology associated with necrosis and high mitotic count; another characterized by the presence of larger cells, with polygonal cytoplasm which may feature rhabdoid morphology; and a third group presenting as high-grade spindle cell tumors often featuring a “herringbone” growth pattern [3,4].
SS subtypes share a common genetic alteration: a translocation involving chromosomes X and 18. This translocation results in three alternative fusion products of the SS18 gene (previously known as SYT) (on chromosome 18) with either SSX1, or SSX2 or SSX4 gene (on chromosome X) [1]. This knowledge provides useful ancillary diagnostic tools [1] for identification of the specific translocation by interphase FISH analysis, with probes flanking the breakpoints, and amplification of the specific chimeric transcript by RT-PCR techniques [5].
SS rarely occurs in unusual sites including: the head and neck region [6,7], mediastinum [8], larynx and hypopharynx [9], nerves [10], blood vessels [11,12], heart [13], abdominal cavity [14], gastrointestinal tract [15-23] and liver [24,25]. In routine activity it may be difficult to distinguish SS occurring in the digestive tract from other mesenchymal neoplasms, mainly GIST (gastrointestinal stromal tumour). However, this distinction is crucial to ensure a correct therapeutic approach. Here we report the clinicopathological, immunohistochemical and molecular genetic data of fifteen cases of SS occurring in the digestive system. We aim to improve knowledge on this entity and stress the importance of correct differential diagnosis for appropriate therapeutic management.

Materials and methods

Patients

Fifteen cases of SS of the abdominal viscera were collected from three Italian institutions, the consultation files of one of the Authors (APDT) and Departments of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. Patients’ clinical records were retrieved. Follow-up information was available for 11 patients (Table 1). All samples were handled in a coded fashion, and all procedures were performed according to the ethical guidelines of the local institutions.
Table 1
Clinicopathologic features of 14 synovial sarcomas of the digestive system
Case #
Site
Size
Gender
Age
Follow up
Metastases
1
Gastric body
8
F
50
Lost
 
2
Cardias
6
M
36
AWD@36
Liver
3
Gastric
2
M
37
Recent
 
4
Gastric
NR
M
26
AWD@185
Liver, Lungs
5
Gastric
10
M
58
DOD@6
 
6
Gastric
10
M
21
Lost@48
 
7
Gastric
6
M
36
Lost@12
 
8
Gastric
3.8
F
54
Recent
 
9
Epigastrium
13
F
57
AWD@7
 
10
Ileum
8
M
49
DOD@60
 
11
Large bowel
5.5
M
40
NED@132
 
12
Rectosigmoid colon
6.3
F
44
DOD@47
 
13
Rectosigmoid colon
6.3
F
44
DOD@47
 
14
Ileum/Colon
7.5
M
17
NED@108
 
15
Liver
15
M
61
AWD@12
 
Legend: Size is given in centimeter; NR: not reported, Follow Up is in months; DOD: dead of disease; NED: not evidence of disease; AWD: alive with disease; Lost: lost to follow up.

Pathology assessment and immunohistochemistry

All the cases were reviewed for diagnostic confirmation and both necrosis extent and mitoses count evaluated, grading provided according to French National Federation of Cancer Centers (FNLCC) (Table 2). In a subset of cases neoadjuvant chemotherapy was applied and pre-chemo biopsies were not available (Table 2); the values for mitoses and necrosis are no longer relevant for these cases as pre-treated specimens cannot be accurately graded under the FNCLCC system.
Table 2
Morphological features of 15 synovial sarcomas of the digestive system
Case #
Type
Mitoses
Necrosis
Grading
Involvement of
     
Perivisceral soft tissue
Peritoneum
Adjacent organ
1
M
7
1
2
None
None
None
2
PD
11
1
2
Adventitial tissue
Yes
None
3
M
6
0
2
None
None
None
4
M
P
P
P
Adventitial tissue
Yes
Pancreas
5
M
12
1
2
Adventitial tissue
Yes
Pancreas
6
M
P
P
P
None
None
None
7
B
27
1
3
None
None
None
8
M
14
1
2
None
None
None
9
M
8
2
3
Stomach, duodenum and liver
Yes
None
10
M
5
1
2
None
None
None
11
M
13
1
2
Perivisceral adipose tissue
None
None
12
PD
P
P
P
Perirectal adipose tissue
None
None
13
PD
P
P
P
None
None
None
14
M
4
1
2
None
None
None
15
M
P
P
P
None
None
None
Legend: M: monophasic, B: biphasic, PD: poorly differentiated, mitoses are per 10 HPF, P: pretreated. Necrosis is reported as: 0 for no necrosis, 1 for <50% tumor necrosis, 2 for ≥ 50% tumor necrosis.
Immunostaining was performed for EMA, cytokeratin AE1/AE3, SMA, Desmin, CD34, CD117, S-100, CD99, CD56 and TLE1. Four-μm sections of formalin-fixed paraffin-embedded material were used according to standard laboratory procedures. Details of the antibodies used are given in Table 3.
Table 3
Details of the antibodies used in this study
Antibody
Clone
Producer
Diluition
Antigen retrieval
EMA
E29
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
CKAE1/AE3
Polyclonal
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
SMA
1A4
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
DESM
D33
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
CD34
QBend-10
Dako, Glostrup, Denmark
prediluited
Flex (Dako)
CD117
Polyclonal
Dako, Glostrup, Denmark
1/700
Flex (Dako)
S-100
Polyclonal
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
TLE1
c-9121
Santa Cruz Biochemicals, Santa Cruz, CA, USA
1:100
Flex (Dako)
BCL2
124
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
CD56
123C3
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
CD99
MIC2
Dako, Glostrup, Denmark
Prediluted
Flex (Dako)
DOG1
K9
Novocastra, NewCastle, UK
1:100
Flex (Dako)

Conventional karyotype

For case 14 conventional karyotype was performed. Cell culture, harvest conditions, and karyotyping were performed according to standard protocols.

Interphase FISH

Fluorescent in situ hybridisation (FISH) was performed on 5 μm paraffin-embedded tissue sections using the LSI SYT (18q11.2) Dual Color Break Apart Rearrangement Probe set (Vysis, Downers Grove, IL, USA).
Hybridisation was performed according to the manufacturer’s protocol. Slides were mounted and counterstained with anti-fade DAPI (Vysis, Downers Grove, IL, USA), visualized using an epifluorescent microscope (Olympus BX61) and analysed with FISH analysis software (Genetix-Cytovision 4.5.1). 300 interphase nuclei were analyzed.

Q-PCR

Ten to fifteen 15 μm-thick sections from paraffin-embedded tissue were de-paraffinized twice using xylene, washed twice with absolute ethanol followed by TNE1X, resuspended in 250 μl of ATL buffer (Qiagen) with the addition of proteinase K (Qiagen), and incubated for 72 hours at 55°C under moderate shaking. The percentage of tumor cells, as calculated from the HE-stained slides, was at least 70%. Subsequently, RNA was extracted with TRIzol-LS Reagent (Gibco BRL), according to the manufacturer’s instructions. RNA pellets were resuspended in 10–20 μl of RNAse-free water and stored at −80°C. 5 μg of total RNA were reverse transcribed in a total volume of 20 μl using specific reverse primers for SSX and BETA2M genes, respectively. Samples were incubated at 42°C for 1 hour, then at 72°C for 15 minutes. PCR amplification of each sample and a 1:20 dilution were performed in duplicate using 96-well plates in 25 μl reaction mixture containing 300 nM of each primer, 200 nM of each probe (SSX1-SSX2) or 100 nM probe BETA2M and 2X TaqMan Gene Expression Master Mix (Applied Biosystems, CA), on Applied Biosystems StepOnePlus Real-Time PCR Systems (Applied Byosystem). (For primer and probe sequences, see Table 4). Thermal cycling conditions were 2 minutes at 50°C, 10 minutes at 95°C, then 50 cycles for three PCR steps consisting of 30 seconds at 95°C and 1 minute at 60°C. Eight cases were studied by Q-PCR, for all of them a positive control product was amplified.
Table 4
Sequences of the primers and probes used in this study
PRIMER/PROBE name
Sequence
SS18 (forward)
AGAGGCCTTATGGATATGACCAGAT
SSXC (reverse)
CRTTTTGTGGGCCAGATGC
BETA2M+ (forward)
TGACTTTGTCACAGCCCAAGATA
BETA2M- (reverse)
AATCCAAATGCGGCATCTTC
SSX1 probe
TCCCTTCGAATCATTTTCGTCCTCTGCT
SSX2 probe
TCTGGCACTTCCTCCGAATCATTTCCTT
BETA2M probe
TGATGCTGCTTACATGTCTCGATCCCA

Results

In the identified fourteen cases of digestive system SS a male prevalence was found: male/female ratio was 3:1. Age at clinical presentation ranged from 17 to 61 years (median 44 years) (Table 1). Size ranged from 2 cm to 15 cm (median 8 cm) (Table 1). Eight cases were occurring in the stomach, one case in the epigastric region, one case in the ileum, three cases in the large intestine, one case was involving both the terminal ileum and the caecum and one case in the liver (Table 1).
Five of the eight tumors arising in the stomach tract were confined to the wall (without serosal involvement); one extended into the perivisceral soft tissue, peritoneum and omentum (Figure 1A) and two involved the pancreas (Table 2). The tumor located in the epigastric region was adherent to the stomach and duodenal wall and focally attached to the liver (Table 2). Three tumors were involving the large bowel with extension in the perivisceral adipose tissue in two of them. The case affecting the ileum was limited to the ileum wall, similarly also the case involving both ileum and caecum was limited to the visceral wall (Table 2). The one in the liver was confined to the parenchyma without ulceration of the Glisson’s capsule (Table 2).
Microscopically, eleven of the tumours consisted of monotonous spindle cell proliferation, with scant intercellular eosinophilic collagenous stroma (Figure 1B) (Table 2). A focal HPC-like vascular network was observed. Three cases showed poorly differentiated features (Figure 1C) and one showed biphasic features with both spindle cells components and tubules formation (Table 2).
Mitotic count ranged from 4 to 27 mitoses/10 HPF (median 9.5) (Table 2). Immunoreactivity for EMA was found in all tested cases ranging from focal to strong and diffuse (Figure 1D) (Table 5). Focal positivity for immunostains for cytokeratin AE1-AE3 was found in 8 cases (Table 5). All tested cases were positive for TLE1, BCL2 and CD99 (Table 5). No expression of CD117, SMA, DESMIN, CD34 and S-100 protein was found. DOG1 was focally expressed in one case (case 9, Table 5)
Table 5
Results of the performed immunostains and fusion type in 15 synovial sarcomas of the digestive system
Case #
EMA
CKAE1/AE3
SMA
DESMIN
CD34
CD117
S-100
BCL2
CD99
CD56
DOG1
TLE1
Fusion type
1
+
-
-
-
-
-
-
+
+
+
-
+
SS18-SSX1
2
+
-
-
-
-
-
-
+
+
+
-
+
N/A
3
+
+
-
-
-
-
-
+
+
+
-
+
N/A
4
+
-
NP
NP
NP
-
-
NP
NP
NP
NP
NP
N/A
5
+
-
NP
-
-
-
-
NP
NP
NP
NP
NP
SS18-SSX1
6
+
-
NP
NP
NP
-
-
NP
NP
NP
NP
NP
N/A
7
NP
+
NP
NP
-
-
NP
NP
NP
NP
NP
NP
SS18-SSX2
8
+
+
-
-
-
-
-
+
+
+
-
+
SS18-SSX1
9
+
+
-
-
-
-
-
+
+
+
+
+
N/A
10
+
+
-
-
-
-
-
+
+
+
-
+
SS18-SSX2
11
+
-
-
-
-
-
-
+
+
+
-
+
SS18-SSX2
12
+
+
NP
NP
NP
-
-
+
+
NP
NP
NP
SS18-SSX2
13
+
+
NP
NP
NP
-
-
+
+
NP
NP
NP
SS18-SSX1
14
+
-
NP
-
-
-
-
+
+
NP
NP
NP
N/A
15
+
+
-
-
-
-
-
+
+
+
-
+
N/A
.
All cases showed SS18 gene region rearrangement. Case 14 showed 46, XY, t(X; 18)(p11;q11) karyotype (data not shown). The remaining cases were assessed either by interphase FISH (Figure 1E) or by RT-PCR or both. Eight cases were analyzed by RT-PCR: either SS18-SSX2 fusion transcript or SS18-SSX1 fusion transcript was identified in 4 cases each (Figure 1F, Table 5).
Follow up was available for 11 patients: range from 6 to 185 months (47 median) (Table 1).
Based on clinical, morphological, immunophenotypical and molecular data a diagnosis of primary SS of the digestive tract was formulated: monophasic synovial sarcoma in eleven cases, biphasic SS in one case and poorly differentiated SS in three cases.

Discussion

SS is characterized by a complex, relatively distinctive immunophenotype, which includes co-expression of mesenchymal (vimentin) and epithelial markers (cytokeratins and EMA). Since morphological features of epithelial differentiation may be very subtle, immunostains are a valuable diagnostic aid. Cytokeratins tend to decorate most biphasic synovial sarcomas, but when dealing with the monophasic subtype, the percentage of immunopositivity falls to 60%-70%. Interestingly, cytokeratin immunoreactivity has been demonstrated only in 50% of PDSS [3] and high molecular weight cytokeratins proved to be more sensitive than low molecular weight cytokeratins. The most sensitive marker of epithelial differentiation is EMA, which stains most cases of PDSS, including those that fail to express cytokeratins [3]. Between 30% and 60% of SS express S-100 protein leading to potential confusion when dealing with the differential diagnosis between monophasic spindle-cell SS and MPNST [26,27]. To avoid diagnostic pitfalls caused by the use of single antibody, it is therefore strongly recommended to perform a panel of immunohistochemical markers.
The diagnosis of biphasic synovial sarcoma is usually straightforward, even for cases occurring in the digestive system. Regarding monophasic SS in the digestive system, the main differential diagnosis is with GIST: any mesenchymal lesion arising in the GI tract would naturally be suggestive of a diagnosis of GIST and CD117 negativity “per se” does not rule out such a possibility [28]. GISTs are usually composed of short spindled and/or epithelioid cells with perinuclear vacuolization and nuclear palisading. Recognition of the histological features, and the combination of CD117 with DOG1 staining is sufficient in the majority of cases to confirm the diagnosis of GIST [29]. However caution should be used in interpreting the results of immunohistochemistry since synovial sarcoma of the digestive system may show focal positivity for DOG 1 [30], as also exemplified in our case series. Remarkably sporadic GIST cases have been reported to be positive for cytokeratin [31,32], however EMA positivity is exceptional in GIST [23]. Leiomyosarcomas and malignant spindle cell melanomas are considered in the differential diagnosis with monophasic SS of the digestive system. However they are characterized by a higher pleomorphism and stronger immunostaining for smooth muscle markers and melanocytic markers, respectively, can usually confirm the diagnoses.
Sarcomatoid carcinoma may also be considered in the differential diagnosis, however it often exhibits conspicuous pleomorphism, stronger expression of epithelial markers, and area of conventional carcinoma are often associated with the sarcomatoid component.
Gastrointestinal clear cell sarcoma may be very difficult to distinguish form digestive system SS [33,34], also because, as previously mentioned, SS may be positive for S100 staining [26,27]. However gastrointestinal clear cell sarcomas are usually negative for epithelial markers and show rearrangement of the EWSR1 gene [33,34]. Remarkably clear cells sarcomas occurring in the gastrointestinal tract differ from clear cell sarcomas of the soft tissue. In fact they display scattered osteoclast-type giant cells and only partial melanocytic differentiation, being debated to be a separate entity. For this reason Stockman et al. proposed to call it malignant gastrointestinal neuroectodermal tumor [33].
PD SS may resemble other small round cell tumors including Ewing Sarcoma/PNET, neuroblastoma, rhabdomyosarcoma and lymphoma [1]. Remarkably CD99 antigen is found also in SS [35] and epithelial markers may be absent in PDSS and focally present in Ewing Sarcoma/PNET [1]. In this setting, demonstration of rearrangement of SSX18 or EWSR1 is crucial for differentiating respectively PDSS from Ewing Sarcoma/PNET [1]. Also it should be remembered that CD99 positivity in synovial sarcomas does not feature the typical crisp membrane staining most often observed in Ewing’s sarcoma.
Cytogenetically, all SS variants are characterized by the reciprocal translocation t(X;18)(p11.2;q11.2), which leads, at molecular level, to the fusion between the synovial sarcoma translocation gene on chromosome 18 (SS18) and one of the synovial sarcoma X breakpoint (SSX) genes on chromosome X: SSX1, SSX2 and rarely with SSX4 [36-38]. Interestingly, the SS18-SSX1 translocation seems to be associated with the biphasic type [39]. The SS18 gene is unrelated to any other known gene but contains a glutamine-proline-glycine-rich region, suggestive of a transcriptional activation domain. The SSX1, SSX2 and SSX4 genes are also unrelated to other known genes and encode proteins that show a remarkable homology.
Despite initial attempt to correlate fusion type with a significantly longer disease-free survival [39,40] morphological grading is still the most important prognostic indicator [41]. Furthermore, tumor size (>5 cm), presence of neural infiltration and vascular invasion, p53 overexpression, and high Ki67 proliferation index identify subsets of SS patients with increased risk of tumor relapse [42-44].

Conclusions

Recognizing SS is of paramount importance to ensure the right therapy, especially because SS is known to respond to ifosfamide-based systemic treatments [45]. In the clinical setting of SS of the digestive system the use of ancillary molecular techniques improves the diagnostic accuracy.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The Creative Commons Public Domain Dedication waiver (https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SR: experimental design, drafting of the manuscript; SR, FC, MAM, MS, LL, LV, MCDO: commenting on the final manuscript; GM, MCM, AG: collecting new cases; AL, APDT: collecting new cases, drafting and editing of the manuscript. All authors have read and given final approval of the version to be published.
Literatur
1.
Zurück zum Zitat Suurmeijer AJH, de Bruijn D, Geurts van Kessel A, Miettinen MM. Synovial Sarcoma. Lyon: IARC Press; 2013. Suurmeijer AJH, de Bruijn D, Geurts van Kessel A, Miettinen MM. Synovial Sarcoma. Lyon: IARC Press; 2013.
2.
Zurück zum Zitat Majeste RM, Beckman EN. Synovial sarcoma with an overwhelming epithelial component. Cancer. 1988;61:2527–31.CrossRefPubMed Majeste RM, Beckman EN. Synovial sarcoma with an overwhelming epithelial component. Cancer. 1988;61:2527–31.CrossRefPubMed
3.
Zurück zum Zitat Folpe AL, Schmidt RA, Chapman D, Gown AM. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol. 1998;22:673–82.CrossRefPubMed Folpe AL, Schmidt RA, Chapman D, Gown AM. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol. 1998;22:673–82.CrossRefPubMed
4.
Zurück zum Zitat Van de Rijn M, Barr FG, Xiong QB, Hedges M, Shipley J, Fisher C. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol. 1999;23:106–12.CrossRefPubMed Van de Rijn M, Barr FG, Xiong QB, Hedges M, Shipley J, Fisher C. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol. 1999;23:106–12.CrossRefPubMed
5.
Zurück zum Zitat Coindre JM, Pelmus M, Hostein I, Lussan C, Bui BN, Guillou L. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer. 2003;98:2700–7.CrossRefPubMed Coindre JM, Pelmus M, Hostein I, Lussan C, Bui BN, Guillou L. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer. 2003;98:2700–7.CrossRefPubMed
6.
Zurück zum Zitat Batsakis JG, Nishiyama RH, Sullinger GD. Synovial sarcomas of the neck. Arch Otolaryngol. 1967;85:327–31.CrossRefPubMed Batsakis JG, Nishiyama RH, Sullinger GD. Synovial sarcomas of the neck. Arch Otolaryngol. 1967;85:327–31.CrossRefPubMed
7.
Zurück zum Zitat Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a follow up study of 24 cases. Cancer. 1975;35:1243–53.CrossRefPubMed Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a follow up study of 24 cases. Cancer. 1975;35:1243–53.CrossRefPubMed
8.
Zurück zum Zitat Witkin GB, Miettinen M, Rosai J. A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases. Am J Surg Pathol. 1989;13:490–9.CrossRefPubMed Witkin GB, Miettinen M, Rosai J. A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases. Am J Surg Pathol. 1989;13:490–9.CrossRefPubMed
9.
Zurück zum Zitat Dei Tos AP, Dal Cin P, Sciot R, Furlanetto A, Da Mosto MC, Giannini C, et al. Synovial sarcoma of the larynx and hypopharynx. Ann Otol Rhinol Laryngol. 1998;107:1080–5.CrossRefPubMed Dei Tos AP, Dal Cin P, Sciot R, Furlanetto A, Da Mosto MC, Giannini C, et al. Synovial sarcoma of the larynx and hypopharynx. Ann Otol Rhinol Laryngol. 1998;107:1080–5.CrossRefPubMed
10.
Zurück zum Zitat O’Connell JX, Browne WL, Gropper PT, Berean KW. Intraneural biphasic synovial sarcoma: an alternative “glandular” tumor of peripheral nerve. Mod Pathol. 1996;9:738–41.PubMed O’Connell JX, Browne WL, Gropper PT, Berean KW. Intraneural biphasic synovial sarcoma: an alternative “glandular” tumor of peripheral nerve. Mod Pathol. 1996;9:738–41.PubMed
11.
Zurück zum Zitat Miettinen M, Santavirta S, Slatis P. Intravascular synovial sarcoma. Hum Pathol. 1987;18:1075–7.CrossRefPubMed Miettinen M, Santavirta S, Slatis P. Intravascular synovial sarcoma. Hum Pathol. 1987;18:1075–7.CrossRefPubMed
12.
Zurück zum Zitat Shaw GR, Lais CJ. Fatal intravascular synovial sarcoma in a 31-year-Old woman. Hum Pathol. 1993;24:809–10.CrossRefPubMed Shaw GR, Lais CJ. Fatal intravascular synovial sarcoma in a 31-year-Old woman. Hum Pathol. 1993;24:809–10.CrossRefPubMed
13.
Zurück zum Zitat Hazelbag HM, Szuhai K, Tanke HJ, Rosenberg C, Hogendoorn PCW. Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype. Mod Pathol. 2004;17:1434–9.CrossRefPubMed Hazelbag HM, Szuhai K, Tanke HJ, Rosenberg C, Hogendoorn PCW. Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype. Mod Pathol. 2004;17:1434–9.CrossRefPubMed
14.
15.
Zurück zum Zitat Amr SS, Shihabi NK, Al HH. Synovial sarcoma of the esophagus. Am J Otolaryngol. 1984;5:266–9.CrossRefPubMed Amr SS, Shihabi NK, Al HH. Synovial sarcoma of the esophagus. Am J Otolaryngol. 1984;5:266–9.CrossRefPubMed
16.
Zurück zum Zitat Anton-Pacheco J, Cano I, Cuadros J, Vilarino A, Berchi F. Synovial sarcoma of the esophagus. J Pediatr Surg. 1996;31:1703–5.CrossRefPubMed Anton-Pacheco J, Cano I, Cuadros J, Vilarino A, Berchi F. Synovial sarcoma of the esophagus. J Pediatr Surg. 1996;31:1703–5.CrossRefPubMed
17.
Zurück zum Zitat Bloch MJ, Iozzo RV, Edmunds Jr LH, Brooks JJ. Polypoid synovial sarcoma of the esophagus. Gastroenterology. 1987;92:229–33.PubMed Bloch MJ, Iozzo RV, Edmunds Jr LH, Brooks JJ. Polypoid synovial sarcoma of the esophagus. Gastroenterology. 1987;92:229–33.PubMed
18.
Zurück zum Zitat Habu S, Okamoto E, Toyosaka A, Nakai Y, Takeuchi M. Synovial sarcoma of the esophagus: report of a case. Surg Today. 1998;28:401–4.CrossRefPubMed Habu S, Okamoto E, Toyosaka A, Nakai Y, Takeuchi M. Synovial sarcoma of the esophagus: report of a case. Surg Today. 1998;28:401–4.CrossRefPubMed
19.
Zurück zum Zitat Palmer BV, Levene A, Shaw HJ. Synovial sarcoma of the pharynx and oesophagus. J Laryngol Otol. 1983;97:1173–6.CrossRefPubMed Palmer BV, Levene A, Shaw HJ. Synovial sarcoma of the pharynx and oesophagus. J Laryngol Otol. 1983;97:1173–6.CrossRefPubMed
20.
Zurück zum Zitat Billings SD, Meisner LF, Cummings OW, Tejada E. Synovial sarcoma of the upper digestive tract: a report of two cases with demonstration of the X;18 translocation by fluorescence in situ hybridization. Mod Pathol. 2000;13:68–76.CrossRefPubMed Billings SD, Meisner LF, Cummings OW, Tejada E. Synovial sarcoma of the upper digestive tract: a report of two cases with demonstration of the X;18 translocation by fluorescence in situ hybridization. Mod Pathol. 2000;13:68–76.CrossRefPubMed
21.
Zurück zum Zitat Chan GS, Yuen ST, Chan KW. Synovial sarcoma presenting as a polypoid jejunal mass. Histopathology. 2004;44:191–3.CrossRefPubMed Chan GS, Yuen ST, Chan KW. Synovial sarcoma presenting as a polypoid jejunal mass. Histopathology. 2004;44:191–3.CrossRefPubMed
22.
Zurück zum Zitat Schreiber-Facklam H, Bode-Lesniewska B, Frigerio S, Flury R. Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation. Hum Pathol. 2007;38:946–9.CrossRefPubMed Schreiber-Facklam H, Bode-Lesniewska B, Frigerio S, Flury R. Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation. Hum Pathol. 2007;38:946–9.CrossRefPubMed
23.
Zurück zum Zitat Makhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, et al. Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol. 2008;32:275–81.CrossRefPubMed Makhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, et al. Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol. 2008;32:275–81.CrossRefPubMed
24.
Zurück zum Zitat Srivastava A, Nielsen PG, Dal Cin P, Rosenberg AE. Monophasic synovial sarcoma of the liver. Arch Pathol Lab Med. 2005;129:1047–9.PubMed Srivastava A, Nielsen PG, Dal Cin P, Rosenberg AE. Monophasic synovial sarcoma of the liver. Arch Pathol Lab Med. 2005;129:1047–9.PubMed
25.
Zurück zum Zitat Holla P, Hafez GR, Slukvin I, Kalayoglu M. Synovial sarcoma, a primary liver tumor–a case report. Pathol Res Pract. 2006;202:385–7.CrossRefPubMed Holla P, Hafez GR, Slukvin I, Kalayoglu M. Synovial sarcoma, a primary liver tumor–a case report. Pathol Res Pract. 2006;202:385–7.CrossRefPubMed
26.
Zurück zum Zitat Fisher C, Schofield JB. S-100 protein positive synovial sarcoma. Histopathology. 1991;19:375–7.CrossRefPubMed Fisher C, Schofield JB. S-100 protein positive synovial sarcoma. Histopathology. 1991;19:375–7.CrossRefPubMed
27.
Zurück zum Zitat Guillou L, Wadden C, Kraus MD, Dei Tos AP, Fletcher CDM. S-100 protein reactivity in synovial sarcomas- a potentially frequent diagnostic pitfall: immunohistochemical analysis of 100 cases. Applied Immunohistochemistry. 1996;4:167–75. Guillou L, Wadden C, Kraus MD, Dei Tos AP, Fletcher CDM. S-100 protein reactivity in synovial sarcomas- a potentially frequent diagnostic pitfall: immunohistochemical analysis of 100 cases. Applied Immunohistochemistry. 1996;4:167–75.
28.
Zurück zum Zitat Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889–94.CrossRefPubMed Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889–94.CrossRefPubMed
29.
Zurück zum Zitat Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57:259–70.CrossRefPubMed Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57:259–70.CrossRefPubMed
30.
Zurück zum Zitat Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33:1401–8.CrossRefPubMed Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33:1401–8.CrossRefPubMed
31.
Zurück zum Zitat Rossi G, Sartori G, Valli R, Bertolini F, Bigiani N, Schirosi L, et al. The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour. J Clin Pathol. 2005;58:991–3.CrossRefPubMedCentralPubMed Rossi G, Sartori G, Valli R, Bertolini F, Bigiani N, Schirosi L, et al. The value of c-kit mutational analysis in a cytokeratin positive gastrointestinal stromal tumour. J Clin Pathol. 2005;58:991–3.CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Lippai N, Fule T, Nemeth T, Benedek G, Malyi I, Padi E, et al. Keratin-positive gastrointestinal stromal tumor of the stomach mimicking gastric carcinoma: diagnosis confirmed by c-kit mutation analysis. Diagn Mol Pathol. 2008;17:241–4.CrossRefPubMed Lippai N, Fule T, Nemeth T, Benedek G, Malyi I, Padi E, et al. Keratin-positive gastrointestinal stromal tumor of the stomach mimicking gastric carcinoma: diagnosis confirmed by c-kit mutation analysis. Diagn Mol Pathol. 2008;17:241–4.CrossRefPubMed
33.
Zurück zum Zitat Stockman DL, Miettinen M, Suster S, Spagnolo D, Dominguez-Malagon H, Hornick JL, et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol. 2012;36:857–68.CrossRefPubMed Stockman DL, Miettinen M, Suster S, Spagnolo D, Dominguez-Malagon H, Hornick JL, et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol. 2012;36:857–68.CrossRefPubMed
34.
Zurück zum Zitat D’Amico FE, Ruffolo C, Romeo S, Massani M, Dei Tos AP, Bassi N. Clear cell sarcoma of the ileum: report of a case and review of the literature. Int J Surg Pathol. 2012;20:401–6.CrossRefPubMed D’Amico FE, Ruffolo C, Romeo S, Massani M, Dei Tos AP, Bassi N. Clear cell sarcoma of the ileum: report of a case and review of the literature. Int J Surg Pathol. 2012;20:401–6.CrossRefPubMed
35.
Zurück zum Zitat Dei Tos AP, Wadden C, Calonje E, Sciot R, Pauwels P, Knight JC, et al. Immunohistochemical demonstration of glycoprotein p30/32mic2 (CD99) in synovial sarcoma. Appl Immunohistochem. 1995;3:168–73. Dei Tos AP, Wadden C, Calonje E, Sciot R, Pauwels P, Knight JC, et al. Immunohistochemical demonstration of glycoprotein p30/32mic2 (CD99) in synovial sarcoma. Appl Immunohistochem. 1995;3:168–73.
36.
Zurück zum Zitat Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA, Cooper CS: Fusion of SYT to two genes, SSXI and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J, in press. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA, Cooper CS: Fusion of SYT to two genes, SSXI and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J, in press.
37.
Zurück zum Zitat Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AML, et al. Identification of novel genes, SYT and SSX involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genet. 1994;7:502–8.CrossRefPubMed Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AML, et al. Identification of novel genes, SYT and SSX involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genet. 1994;7:502–8.CrossRefPubMed
38.
Zurück zum Zitat Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J, Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 1995;147:1592–9.PubMedCentralPubMed Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J, Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 1995;147:1592–9.PubMedCentralPubMed
39.
Zurück zum Zitat Kawai A, Woodruff J, Healy JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153–60.CrossRefPubMed Kawai A, Woodruff J, Healy JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153–60.CrossRefPubMed
40.
Zurück zum Zitat Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–40.PubMed Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135–40.PubMed
41.
Zurück zum Zitat Guillou L, Benhattar J, Terrier P, Gallagher G, Jundt G, Stauffer E, et al. SYT-SSX fusion type is not a prognostic factor in synovial sarcoma (SS) patients. A multi-institutional study of 182 cases. Mod Pathol. 2003;16:13A. Guillou L, Benhattar J, Terrier P, Gallagher G, Jundt G, Stauffer E, et al. SYT-SSX fusion type is not a prognostic factor in synovial sarcoma (SS) patients. A multi-institutional study of 182 cases. Mod Pathol. 2003;16:13A.
42.
Zurück zum Zitat Antonescu CR, Leung DH, Dudas M, Ladanyi M, Brennan M, Woodruff JM, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977–83.CrossRefPubMedCentralPubMed Antonescu CR, Leung DH, Dudas M, Ladanyi M, Brennan M, Woodruff JM, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977–83.CrossRefPubMedCentralPubMed
43.
Zurück zum Zitat Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18:2087–94.PubMed Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18:2087–94.PubMed
44.
Zurück zum Zitat Trassard M, Le DV, Hacene K, Terrier P, Ranchere D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19:525–34.PubMed Trassard M, Le DV, Hacene K, Terrier P, Ranchere D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19:525–34.PubMed
45.
Zurück zum Zitat Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627–34.CrossRefPubMed Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627–34.CrossRefPubMed
Metadaten
Titel
Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases
verfasst von
Salvatore Romeo
Sabrina Rossi
Marthelena Acosta Marín
Fabio Canal
Marta Sbaraglia
Licia Laurino
Guido Mazzoleni
Maria Cristina Montesco
Laura Valori
Marta Campo Dell’Orto
Andrea Gianatti
Alexander Joseph Lazar
Angelo Paolo Dei Tos
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Clinical Sarcoma Research / Ausgabe 1/2015
Elektronische ISSN: 2045-3329
DOI
https://doi.org/10.1186/s13569-015-0021-3

Weitere Artikel der Ausgabe 1/2015

Clinical Sarcoma Research 1/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.